Sitrin Capital Management LLC Has $4.73 Million Stock Position in Agilent Technologies, Inc. (NYSE:A)

Sitrin Capital Management LLC increased its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 0.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 35,189 shares of the medical research company’s stock after acquiring an additional 170 shares during the quarter. Agilent Technologies accounts for 2.4% of Sitrin Capital Management LLC’s portfolio, making the stock its 22nd biggest position. Sitrin Capital Management LLC’s holdings in Agilent Technologies were worth $4,727,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the stock. Lake Street Advisors Group LLC grew its stake in Agilent Technologies by 7.1% in the 4th quarter. Lake Street Advisors Group LLC now owns 3,529 shares of the medical research company’s stock valued at $475,000 after purchasing an additional 234 shares during the period. FFT Wealth Management LLC boosted its holdings in shares of Agilent Technologies by 19.7% in the 4th quarter. FFT Wealth Management LLC now owns 3,516 shares of the medical research company’s stock worth $472,000 after buying an additional 578 shares during the last quarter. Impax Asset Management Group plc grew its position in Agilent Technologies by 6.1% during the fourth quarter. Impax Asset Management Group plc now owns 2,829,429 shares of the medical research company’s stock valued at $380,105,000 after buying an additional 161,813 shares during the period. Rothschild Investment LLC grew its position in Agilent Technologies by 19.2% during the fourth quarter. Rothschild Investment LLC now owns 491 shares of the medical research company’s stock valued at $66,000 after buying an additional 79 shares during the period. Finally, IFP Advisors Inc increased its holdings in Agilent Technologies by 17.7% during the fourth quarter. IFP Advisors Inc now owns 458 shares of the medical research company’s stock worth $62,000 after buying an additional 69 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on A shares. Barclays upgraded shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and boosted their target price for the company from $135.00 to $145.00 in a research note on Monday, February 10th. JPMorgan Chase & Co. dropped their price objective on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 26th. Wells Fargo & Company decreased their target price on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research report on Monday, December 9th. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Finally, Citigroup lifted their price objective on Agilent Technologies to $165.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $144.38.

Agilent Technologies Price Performance

NYSE:A opened at $134.05 on Wednesday. Agilent Technologies, Inc. has a 52-week low of $124.16 and a 52-week high of $155.35. The stock has a fifty day moving average of $140.87 and a 200 day moving average of $139.31. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.58 and a current ratio of 2.09. The firm has a market capitalization of $38.24 billion, a price-to-earnings ratio of 30.33, a P/E/G ratio of 3.66 and a beta of 1.07.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. The firm had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The company’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the company posted $1.38 EPS. On average, research analysts expect that Agilent Technologies, Inc. will post 5.56 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be given a dividend of $0.248 per share. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 annualized dividend and a yield of 0.74%. Agilent Technologies’s payout ratio is presently 22.40%.

Insiders Place Their Bets

In other news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the transaction, the chief executive officer now directly owns 39,652 shares in the company, valued at approximately $5,947,800. This represents a 4.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.